Seaport Therapeutics, Inc.
SPTX
Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company employs its proprietary Glyph platform to address limitations of clinically validated mechanisms, such as high first-pass metabolism, low bioavailability, and side effects, enabling innovative therapies with established efficacy and safety profiles. Seaport Therapeutics targets the neuropsychiatry sector within pharmaceuticals and biotech, aiming to deliver leading treatment options that improve patient outcomes. Its pipeline advances antidepressants and anxiolytics derived from these optimized mechanisms. With a team experienced in neuropsychiatry drug discovery and development, Seaport Therapeutics operates at the intersection of cutting-edge platform technology and targeted therapeutic innovation. Founded in 2024 and headquartered in Boston, Massachusetts, the company plays a role in advancing accessible oral treatments for serious mental health conditions in the competitive biopharmaceutical market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$75M
▼ -59.7% YoY
Op. Margin
–
ROIC
-1367.35%
▼ -540.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$78M
▼ -163.3% YoY
Op. Cash Flow (TTM)
-$78M
▼ -163.1% YoY
Net Debt
-$211M
Net Cash Position
Cash & Equiv.
$216M
Continue Research
Peers
Biotechnology · Pick stocks to compare with SPTX
Held by ETFs
SPTX is in 3 US ETFs. The largest of them, with SPTX's weight in each:
Seaport Therapeutics (SPTX) in two numbers
Questions about Seaport Therapeutics
Is Seaport Therapeutics a high-quality business?
Seaport Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$211M, and its weakest is return on capital at -1367.3%. The Quality tab shows every check against its target.
Does Seaport Therapeutics (SPTX) pay a dividend?
No. Seaport Therapeutics (SPTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SPTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.